ZNTL Logo

Zentalis Pharmaceuticals, Inc. (ZNTL) 

NASDAQ
Market Cap
$228.05M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
773 of 774
Rank in Industry
431 of 432

Largest Insider Buys in Sector

ZNTL Stock Price History Chart

ZNTL Stock Performance

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant …

Insider Activity of Zentalis Pharmaceuticals, Inc.

Over the last 12 months, insiders at Zentalis Pharmaceuticals, Inc. have bought $0 and sold $495,115 worth of Zentalis Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Zentalis Pharmaceuticals, Inc. have bought $45.2M and sold $27.55M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $51,448 was made by Blackwell Kimberly (Chief Executive Officer) on 2023‑11‑13.

List of Insider Buy and Sell Transactions, Zentalis Pharmaceuticals, Inc.

2024-10-04SalePrincipal Accounting Officer
1,603
0.0019%
$3.18$5,098-7.42%
2024-05-31SalePresident, Interim CFO
9,597
0.0136%
$11.98$114,972-70.37%
2024-05-09SaleChief Medical Officer
3,356
0.0048%
$12.62$42,353-70.20%
2024-02-12SalePresident
1,173
0.0016%
$11.44$13,419-9.13%
2024-02-12SaleChief Financial Officer
2,573
0.0036%
$11.44$29,435-9.13%
2024-02-02SalePresident
11,552
0.0155%
$11.54$133,310-5.18%
2024-02-02SaleChief Financial Officer
8,669
0.0116%
$11.54$100,040-5.18%
2024-02-02SaleChief Scientific Officer
1,585
0.0021%
$11.54$18,291-5.18%
2024-02-02SaleChief Legal Officer
3,310
0.0044%
$11.54$38,197-5.18%
2023-11-13PurchaseChief Executive Officer
5,000
0.0071%
$10.29$51,448+12.91%
2023-11-10Purchasedirector
17,000
0.0243%
$9.88$167,943+18.22%
2023-10-04SaleChief Scientific Officer
6,068
0.0084%
$19.50$118,355-39.88%
2023-10-04SaleChief Financial Officer
5,482
0.0076%
$19.50$106,926-39.88%
2023-10-04SaleChief Medical Officer
10,628
0.0148%
$19.50$207,298-39.88%
2023-09-11Saledirector
5,000
0.0071%
$25.05$125,238-49.22%
2023-06-20Purchase10 percent owner
4.76M
6.3802%
$22.66$107.86M-48.63%
2023-05-31SalePresident
27,768
0.0473%
$26.27$729,506-41.32%
2023-05-26SaleChief Scientific Officer
80,000
0.1348%
$30.02$2.4M-48.82%
2023-02-14SaleChief Scientific Officer
6,500
0.0109%
$19.98$129,873-3.41%
2023-02-14SalePresident
8,501
0.0143%
$19.96$169,706-3.41%

Insider Historical Profitability

37.54%
Epperly Melissa B,Chief Financial Officer
451449
0.6335%
$3.20318+21.94%
Matrix Capital Management Company, LP10 percent owner
13959973
19.5887%
$3.2010<0.0001%
VIKING GLOBAL INVESTORS LP10 percent owner
3943284
5.5332%
$3.2011+70.78%
SUN ANTHONY YPresident & CEO
1175589
1.6496%
$3.20130+70.78%
Bunker Kevin D.Chief Scientific Officer
859089
1.2055%
$3.20141+70.78%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Matrix Capital Management Company, L.P.$220.01M19.6613.96M0%+$02.04
Eventide Asset Management$182.42M16.311.57M+0.13%+$233,972.962.95
Fidelity Investments$167.75M14.9910.64M+2.97%+$4.84M0.01
BlackRock$73.22M6.544.65M-0.84%-$618,059.93<0.01
The Vanguard Group$69.32M6.194.4M-17.79%-$15M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.